| Project/Area Number |
15590352
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Experimental pathology
|
|---|
| Research Institution | University of the Ryukyus |
|---|
Principal Investigator |
SUZUI Masumi University of the Ryukyus, Faculty of Medicine, Associate Professor, 医学部, 助教授 (30347158)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YOSHIMI Naoki University of the Ryukyus, Faculty of Medicine, Professor, 医学部, 教授 (30166996)
MORIOKA Takamitsu University of the Ryukyus, Faculty of Medicine, Instructor, 医学部, 助手 (70253961)
|
|---|
| Project Period (FY) |
2003 – 2004
|
| Project Status |
Completed (Fiscal Year 2004)
|
| Budget Amount *help |
¥3,100,000 (Direct Cost: ¥3,100,000)
Fiscal Year 2004: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 2003: ¥2,500,000 (Direct Cost: ¥2,500,000)
|
|---|
| Keywords | acyclic retinoid / p21^<CIP1> / RARβ / hepatoma / esophageal carcinoma / head and neck carcinoma / retinoid / chemoprevention / acyclic retinid / がん予防 |
|---|
| Research Abstract |
Acyclic retinoid(ACR), a novel synthetic retinoid, can prevent the recurrence of hepatomas after surgical resection of primary tumors, but the molecular mechanisms by which ACR exerts anti-tumor effects are not known. In the present studies we found that growth inhibition of human hepatoma cells by ACR is associated with induction of p21^<CIP1> and inhibition of expression of cyclin D1. We also found that ACR activates retinoic acid receptor β and induces transcriptional activation of p21^<CIP1> in human hepatoma, and head and neck and esophageal squamous cell carcinoma cells. These novel effects of ACR suggest that this agent might be useful in the chemoprevention and therapy of various malignancies. Furthermore, the combination of ACR and OSI461, a potent derivative of exisulind, exerted synergistic inhibition of the growth of HepG2 cells. This result suggests that the combination of ACR and OSI461 might be an effective regimen for the chemoprevention and chemotherapy of human hepatoma and possibly other malignancies.
|
